The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial
In: Beneficial MicrobesDivisions of Nephrology, China Medical University Hospital, 2 Yue-Der Road, Taichung 404, Taiwan
Department of Internal Medicine, College of Medicine, China Medical University, 2 Yue-Der Road, Taichung 404, Taiwan
Search for other papers by I.-K. Wang in
Current site
Google Scholar
Search for other papers by Y.-Y Wu in
Current site
Google Scholar
Search for other papers by Y.-F Yang in
Current site
Google Scholar
Search for other papers by I.-W. Ting in
Current site
Google Scholar
Search for other papers by C.-C. Lin in
Current site
Google Scholar
Search for other papers by T.-H. Yen in
Current site
Google Scholar
Search for other papers by J.-H. Chen in
Current site
Google Scholar
Search for other papers by C.-H. Wang in
Current site
Google Scholar
Search for other papers by C.-C. Huang in
Current site
Google Scholar
Search for other papers by H.-C. Lin in
Current site
Google Scholar
Inflammatory markers such as interleukin (IL)-6 and tumour necrosis factor-alpha (TNF-α) are elevated in dialysis patients and can predict cardiovascular events and all-cause mortality. Endotoxin is an important source and also another marker of inflammation in patients with chronic kidney disease. The aim of this study was to evaluate the impact of oral probiotics on serum levels of endotoxemia and cytokines in peritoneal dialysis (PD) patients. The decline of residual renal function, peritonitis episodes, and cardiovascular events were also recorded. From July 2011 to June 2012, a randomised, double-blind, placebo-controlled trial was conducted in PD patients. The intervention group received one capsule of probiotics containing 109 cfu Bifobacterium bifidum A218, 109 cfu Bifidobacterium catenulatum A302, 109 cfu Bifidobacterium longum A101, and 109 cfu Lactobacillus plantarum A87 daily for six months, while the placebo group received similar capsules containing maltodextrin for the same duration. Levels of serum TNF-α, interferon gamma, IL-5, IL-6, IL-10, IL-17, and endotoxin were measured before and six months after intervention. 39 patients completed the study (21 in the probiotics group and 18 in the placebo group). In patients receiving probiotics, levels of serum TNF-α, IL-5, IL-6, and endotoxin significantly decreased after six months of treatment, while levels of serum IL-10 significantly increased. In contrast, there were no significant changes in levels of serum cytokines and endotoxin in the placebo group after six months. In addition, the residual renal function was preserved in patients receiving probiotics. In conclusion, probiotics could significantly reduce the serum levels of endotoxin, pro-inflammatory cytokines (TNF-α and IL-6), IL-5, increase the serum levels of anti-inflammatory cytokine (IL-10), and preserve residual renal function in PD patients.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Anders, H.J., Andersen, K. and Stecher, B., 2013. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney International 83: 1010-1016.
'The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease ' () 83 Kidney International : 1010 -1016.
-
Bargman, J.M., Thorpe, K.E. and Churchill, D.N., 2001. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the Canusa study. Journal of the American Society of Nephrology 12: 2158-2162.
'Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the Canusa study ' () 12 Journal of the American Society of Nephrology : 2158 -2162.
-
Borruel, N., Carol, M., Casellas, F., Antolin, M., De Lara, F., Espin, E., Naval, J., Guarner, F. and Malagelada, J.R., 2002. Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 51: 659-664.
'Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria ' () 51 Gut : 659 -664.
-
Bosshart, H. and Heinzelmann, M., 2007. Targeting bacterial endotoxin: two sides of a coin. Annals of the New York Academy of Sciences 1096: 1-17.
'Targeting bacterial endotoxin: two sides of a coin ' () 1096 Annals of the New York Academy of Sciences : 1 -17.
-
Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B., 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology 13: 236-243.
'Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria ' () 13 World Journal of Gastroenterology : 236 -243.
-
Fuller, R., 1989. Probiotics in man and animals. Journal of Applied Bacteriology 66: 365-378.
'Probiotics in man and animals ' () 66 Journal of Applied Bacteriology : 365 -378.
-
Hauser, A.B., Stinghen, A.E., Goncalves, S.M., Bucharles, S. and Pecoits-Filho, R., 2011. A gut feeling on endotoxemia: causes and consequences in chronic kidney disease. Nephron. Clinical Practice 118: c165-172, discussion c172.
'A gut feeling on endotoxemia: causes and consequences in chronic kidney disease. Nephron. ' () 118 Clinical Practice : c165 -172.
-
Hida, M., Aiba, Y., Sawamura, S., Suzuki, N., Satoh, T. and Koga, Y., 1996. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74: 349-355.
'Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis ' () 74 Nephron : 349 -355.
-
Kimmel, P.L., Phillips, T.M., Simmens, S.J., Peterson, R.A., Weihs, K.L., Alleyne, S., Cruz, I., Yanovski, J.A. and Veis, J.H., 1998. Immunologic function and survival in hemodialysis patients. Kidney International 54: 236-244.
'Immunologic function and survival in hemodialysis patients ' () 54 Kidney International : 236 -244.
-
Kotanko, P., Carter, M. and Levin, N.W., 2006. Intestinal bacterial microflora – a potential source of chronic inflammation in patients with chronic kidney disease. Nephrology Dialysis Transplantation 21: 2057-2060.
'Intestinal bacterial microflora – a potential source of chronic inflammation in patients with chronic kidney disease ' () 21 Nephrology Dialysis Transplantation : 2057 -2060.
-
Magnusson, M., Magnusson, K.E., Sundqvist, T. and Denneberg, T., 1991. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 32: 754-759.
'Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure ' () 32 Gut : 754 -759.
-
Matsumoto, M. and Benno, Y., 2006. Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512. Bioscience, Biotechnology, and Biochemistry 70: 1287-1292.
'Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512 ' () 70 Bioscience, Biotechnology, and Biochemistry : 1287 -1292.
-
McIntyre, C.W., Harrison, L.E., Eldehni, M.T., Jefferies, H.J., Szeto, C.C., John, S.G., Sigrist, M.K., Burton, J.O., Hothi, D., Korsheed, S., Owen, P.J., Lai, K.B. and Li, P.K., 2011. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clinical Journal of the American Society of Nephrology 6: 133-141.
'Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease ' () 6 Clinical Journal of the American Society of Nephrology : 133 -141.
-
Nakabayashi, I., Nakamura, M., Kawakami, K., Ohta, T., Kato, I., Uchida, K. and Yoshida, M., 2011. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrology Dialysis Transplantation 26: 1094-1098.
'Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study ' () 26 Nephrology Dialysis Transplantation : 1094 -1098.
-
Nisbeth, U., Hallgren, R., Eriksson, O. and Danielson, B.G., 1987. Endotoxemia in chronic renal failure. Nephron 45: 93-97.
'Endotoxemia in chronic renal failure ' () 45 Nephron : 93 -97.
-
Pochard, P., Gosset, P., Grangette, C., Andre, C., Tonnel, A.B., Pestel, J. and Mercenier, A., 2002. Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. Journal of Allergy and Clinical Immunology 110: 617-623.
'Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients ' () 110 Journal of Allergy and Clinical Immunology : 617 -623.
-
Raetz, C.R. and Whitfield, C., 2002. Lipopolysaccharide endotoxins. Annual Review of Biochemistry 71: 635-700.
'Lipopolysaccharide endotoxins ' () 71 Annual Review of Biochemistry : 635 -700.
-
Ramezani, A. and Raj, D.S., 2014. The gut microbiome, kidney disease, and targeted interventions. Journal of the American Society of Nephrology 25: 657-670.
'The gut microbiome, kidney disease, and targeted interventions ' () 25 Journal of the American Society of Nephrology : 657 -670.
-
Ranganathan, N., Patel, B.G., Ranganathan, P., Marczely, J., Dheer, R., Pechenyak, B., Dunn, S.R., Verstraete, W., Decroos, K., Mehta, R. and Friedman, E.A., 2006. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO Journal 52: 70-79.
'In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease ' () 52 ASAIO Journal : 70 -79.
-
Ranganathan, N., Ranganathan, P., Friedman, E.A., Joseph, A., Delano, B., Goldfarb, D.S., Tam, P., Rao, A.V., Anteyi, E. and Musso, C.G., 2010. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy 27: 634-647.
'Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease ' () 27 Advances in Therapy : 634 -647.
-
Robinson, D.S. and Kay, A.B., 1996. Role of Th1 and Th2 cells in human allergic disorders. Chemical Immunology 63: 187-203.
'Role of Th1 and Th2 cells in human allergic disorders ' () 63 Chemical Immunology : 187 -203.
-
Rossi, M., Klein, K., Johnson, D.W. and Campbell, K.L., 2012. Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis. International Journal of Nephrology 2012: 673631.
'Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis ', in International Journal of Nephrology , () 673631.
-
Sartor, R.B., 2004. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633.
'Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics ' () 126 Gastroenterology : 1620 -1633.
-
Schiffrin, E.J., Parlesak, A., Bode, C., Bode, J.C., Van ‘t Hof, M.A., Grathwohl, D. and Guigoz, Y., 2009. Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions. British Journal of Nutrition 101: 961-966.
'Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions ' () 101 British Journal of Nutrition : 961 -966.
-
Stenvinkel, P., Barany, P., Heimburger, O., Pecoits-Filho, R. and Lindholm, B., 2002. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney International Supplement: 103-108.
'Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney ', in International Supplement , () 103 -108.
-
Stenvinkel, P., Ketteler, M., Johnson, R.J., Lindholm, B., Pecoits-Filho, R., Riella, M., Heimburger, O., Cederholm, T. and Girndt, M., 2005. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia – the good, the bad, and the ugly. Kidney International 67: 1216-1233.
'IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia – the good, the bad, and the ugly ' () 67 Kidney International : 1216 -1233.
-
Sun, P.P., Perianayagam, M.C. and Jaber, B.L., 2009. Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney International Supplement: S20-S25.
'Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism ', in Kidney International Supplement , () S20 -S25.
-
Szeto, C.C., Kwan, B.C., Chow, K.M., Lai, K.B., Chung, K.Y., Leung, C.B. and Li, P.K., 2008. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clinical Journal of the American Society of Nephrology 3: 431-436.
'Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients ' () 3 Clinical Journal of the American Society of Nephrology : 431 -436.
-
Takayama, F., Taki, K. and Niwa, T., 2003. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. American Journal of Kidney Diseases 41: S142-S145.
'Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis ' () 41 American Journal of Kidney Diseases : S142 -S145.
-
Taki, K., Takayama, F. and Niwa, T., 2005. Beneficial effects of bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. Journal of Renal Nutrition 15: 77-80.
'Beneficial effects of bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients ' () 15 Journal of Renal Nutrition : 77 -80.
-
Termorshuizen, F., Korevaar, J.C., Dekker, F.W., Van Manen, J.G., Boeschoten, E.W. and Krediet, R.T., 2003. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands cooperative study on the adequacy of dialysis (Necosad)-2. American Journal of Kidney Diseases 41: 1293-1302.
'The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands cooperative study on the adequacy of dialysis (Necosad)-2 ' () 41 American Journal of Kidney Diseases : 1293 -1302.
-
Thomas, C.M. and Versalovic, J., 2010. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes 1: 148-163.
'Probiotics-host communication: modulation of signaling pathways in the intestine ' () 1 Gut Microbes : 148 -163.
-
Tobias, P.S. and Ulevitch, R.J., 1994. Lipopolysaccharide-binding protein and CD14 in the lipopolysaccharide-dependent activation of cells. Chest 105: 48S-50S.
'Lipopolysaccharide-binding protein and CD14 in the lipopolysaccharide-dependent activation of cells ' () 105 Chest : 48S -50S.
-
Urao, M., Fujimoto, T., Lane, G.J., Seo, G. and Miyano, T., 1999. Does probiotics administration decrease serum endotoxin levels in infants? Journal Pediatric Surgery 34: 273-276.
'Does probiotics administration decrease serum endotoxin levels in infants? ' () 34 Journal Pediatric Surgery : 273 -276.
-
Wang, I.K., Lai, H.C., Yu, C.J., Liang, C.C., Chang, C.T., Kuo, H.L., Yang, Y.F., Lin, C.C., Lin, H.H., Liu, Y.L., Chang, Y.C., Wu, Y.Y., Chen, C.H., Li, C.Y., Chuang, F.R., Huang, C.C., Lin, C.H. and Lin, H.C., 2012. Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Applied Environmental Microbiology 78: 1107-1112.
'Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients ' () 78 Applied Environmental Microbiology : 1107 -1112.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2271 | 697 | 52 |
| Full Text Views | 129 | 59 | 0 |
| PDF Views & Downloads | 69 | 19 | 0 |
The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial
In: Beneficial MicrobesDivisions of Nephrology, China Medical University Hospital, 2 Yue-Der Road, Taichung 404, Taiwan
Department of Internal Medicine, College of Medicine, China Medical University, 2 Yue-Der Road, Taichung 404, Taiwan
Search for other papers by I.-K. Wang in
Current site
Google Scholar
PubMed
Search for other papers by Y.-Y Wu in
Current site
Google Scholar
PubMed
Search for other papers by Y.-F Yang in
Current site
Google Scholar
PubMed
Search for other papers by I.-W. Ting in
Current site
Google Scholar
PubMed
Search for other papers by C.-C. Lin in
Current site
Google Scholar
PubMed
Search for other papers by T.-H. Yen in
Current site
Google Scholar
PubMed
Search for other papers by J.-H. Chen in
Current site
Google Scholar
PubMed
Search for other papers by C.-H. Wang in
Current site
Google Scholar
PubMed
Search for other papers by C.-C. Huang in
Current site
Google Scholar
PubMed
Search for other papers by H.-C. Lin in
Current site
Google Scholar
PubMed
Inflammatory markers such as interleukin (IL)-6 and tumour necrosis factor-alpha (TNF-α) are elevated in dialysis patients and can predict cardiovascular events and all-cause mortality. Endotoxin is an important source and also another marker of inflammation in patients with chronic kidney disease. The aim of this study was to evaluate the impact of oral probiotics on serum levels of endotoxemia and cytokines in peritoneal dialysis (PD) patients. The decline of residual renal function, peritonitis episodes, and cardiovascular events were also recorded. From July 2011 to June 2012, a randomised, double-blind, placebo-controlled trial was conducted in PD patients. The intervention group received one capsule of probiotics containing 109 cfu Bifobacterium bifidum A218, 109 cfu Bifidobacterium catenulatum A302, 109 cfu Bifidobacterium longum A101, and 109 cfu Lactobacillus plantarum A87 daily for six months, while the placebo group received similar capsules containing maltodextrin for the same duration. Levels of serum TNF-α, interferon gamma, IL-5, IL-6, IL-10, IL-17, and endotoxin were measured before and six months after intervention. 39 patients completed the study (21 in the probiotics group and 18 in the placebo group). In patients receiving probiotics, levels of serum TNF-α, IL-5, IL-6, and endotoxin significantly decreased after six months of treatment, while levels of serum IL-10 significantly increased. In contrast, there were no significant changes in levels of serum cytokines and endotoxin in the placebo group after six months. In addition, the residual renal function was preserved in patients receiving probiotics. In conclusion, probiotics could significantly reduce the serum levels of endotoxin, pro-inflammatory cytokines (TNF-α and IL-6), IL-5, increase the serum levels of anti-inflammatory cytokine (IL-10), and preserve residual renal function in PD patients.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2271 | 697 | 52 |
| Full Text Views | 129 | 59 | 0 |
| PDF Views & Downloads | 69 | 19 | 0 |
